Hyslop DL[au] - Search Results

Year	Number of Results
1988	2
1990	1
1992	3
1994	1
2002	1
2006	1
2018	1
2019	1
2020	1
2024	0

1

Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.

McGill JB, King GL, Berg PH, Price KL, Kles KA, Bastyr EJ, Hyslop DL. McGill JB, et al. Among authors: hyslop dl. Expert Opin Drug Saf. 2006 Nov;5(6):835-45. doi: 10.1517/14740338.5.6.835. Expert Opin Drug Saf. 2006. PMID: 17044810 Review.

2

Efficacy and safety of loracarbef in the treatment of pneumonia.

Hyslop DL. Hyslop DL. Am J Med. 1992 Jun 22;92(6A):65S-69S. doi: 10.1016/0002-9343(92)90610-n. Am J Med. 1992. PMID: 1621747 Review.

3

Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.

Winthrop KL, Harigai M, Genovese MC, Lindsey S, Takeuchi T, Fleischmann R, Bradley JD, Byers NL, Hyslop DL, Issa M, Nishikawa A, Rooney TP, Witt S, Dickson CL, Smolen JS, Dougados M. Winthrop KL, et al. Among authors: hyslop dl. Ann Rheum Dis. 2020 Oct;79(10):1290-1297. doi: 10.1136/annrheumdis-2019-216852. Epub 2020 Aug 11. Ann Rheum Dis. 2020. PMID: 32788396 Free article.

4

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.

Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, Chen L, Dickson CL, Riddle Camp J, Cardillo TE, Ishii T, Winthrop KL. Smolen JS, et al. Among authors: hyslop dl. J Rheumatol. 2019 Jan;46(1):7-18. doi: 10.3899/jrheum.171361. Epub 2018 Sep 15. J Rheumatol. 2019. PMID: 30219772 Free article. Clinical Trial.

5

Sensitive and specific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteers.

Bowsher RR, Compton JA, Kirkwood JA, Place GD, Jones CD, Mabry TE, Hyslop DL, Hatcher BL, DeSante KA. Bowsher RR, et al. Among authors: hyslop dl. Antimicrob Agents Chemother. 1994 Sep;38(9):2134-42. doi: 10.1128/AAC.38.9.2134. Antimicrob Agents Chemother. 1994. PMID: 7811032 Free PMC article.

6

Pharmaceutical risk management: a call to arms for pharmacoepidemiology.

Hyslop DL, Read HA, Masica DN, Kotsanos JG. Hyslop DL, et al. Pharmacoepidemiol Drug Saf. 2002 Jul-Aug;11(5):417-20. doi: 10.1002/pds.757. Pharmacoepidemiol Drug Saf. 2002. PMID: 12271886 No abstract available.

7

Loracarbef (LY163892) versus amoxicillin/clavulanate in bronchopneumonia and lobar pneumonia.

Hyslop DL, Jacobson K, Guerra FJ. Hyslop DL, et al. Clin Ther. 1992 Mar-Apr;14(2):254-67. Clin Ther. 1992. PMID: 1611648 Clinical Trial.

8

Cefaclor treatment of upper and lower respiratory tract infections caused by Moraxella catarrhalis.

Oberlin JA, Hyslop DL. Oberlin JA, et al. Among authors: hyslop dl. Pediatr Infect Dis J. 1990 Jan;9(1):41-4. doi: 10.1097/00006454-199001000-00009. Pediatr Infect Dis J. 1990. PMID: 2105479

9

Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis.

Hyslop DL, Bischoff W. Hyslop DL, et al. Am J Med. 1992 Jun 22;92(6A):86S-94S. doi: 10.1016/0002-9343(92)90614-h. Am J Med. 1992. PMID: 1621752 Clinical Trial.

10

Cefaclor safety profile: a ten-year review.

Hyslop DL. Hyslop DL. Clin Ther. 1988;11 Suppl A:83-94. Clin Ther. 1988. PMID: 3242837 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

11 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year